ClinicalTrials.gg

Program

zagociguat

Also written as “zagociguat 15mg”, “CY6463” and “IW-6463”.

Its studies are mostly in Acidosis, Lactic · Alzheimer Disease · MELAS Syndrome · Schizophrenia, led by Tisento Therapeutics.

Furthest: phase 2, since Jul 14, 20207 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tisento Therapeutics70 open or runningphase 2since Jul 14, 2020Feb 20, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2019First study: phase 1 study in OtherFirst studyNCT03856827 · 110 enrolled · Netherlands
  2. Jan 21, 2020Phase 1 study in OtherNCT04240158 · 24 enrolled · Netherlands
  3. Jul 14, 2020Phase 2 study in MELAS SyndromeNCT04475549 · 8 enrolled · United States
  4. Mar 11, 2021Phase 2 study in Alzheimer DiseaseNCT04798989 · 12 enrolled · United States
  5. Jul 15, 2021Phase 1 study in SchizophreniaNCT04972227 · 48 enrolled · United States
  6. May 2, 2024Phase 2 study in Mitochondrial encephalopathyNCT06402123 · 43 enrolled · United States, Australia, Canada and more
  7. Apr 28, 2025Phase 2 study in Mitochondrial encephalopathyNCT06961344 · 37 enrolled · United States, Australia, Germany and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06961344Mitochondrial encephalopathy · United States, Australia, Germany and more2TerminatedOct 29, 202637
NCT06402123Mitochondrial encephalopathy · United States, Australia, Canada and more2CompletedJun 29, 202643
NCT04972227Schizophrenia · United States1CompletedApr 18, 202248
NCT04798989Alzheimer Disease · United States2TerminatedNov 28, 202212
NCT04475549MELAS Syndrome · United States2TerminatedJan 23, 20228
NCT04240158Other · Netherlands1TerminatedMay 22, 202024
NCT03856827Other · Netherlands1CompletedOct 22, 2019110

How it is read

Names in the registry

  • “zagociguat 15mg”, 2 entries
  • “CY6463”, 2 entries
  • “IW-6463”, 2 entries
  • “zagociguat 30mg”, 1 entry
  • “IW-6463 Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.